QualityStocks
  The QualityStocks Daily Newsletter for Wednesday, Sept. 1st 2010 Blog  |  Video  |  Market Basics  |  Quotes & News  |  Clients  |  Partners  |  About Us  |  Contact Us

Today's Top 3 Investment Newsletters

1.

MicrocapVoice (INOL)

2.

OTC Picks (BETM)

3.

Stock Traders Chat (FONM)


The QualityStocks Daily

Inolife Technologies, Inc. (INOL)

Microcap Voice reported today on Inolife Technologies, Inc. (INOL), and we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

InoLife Technologies, Inc. engages in human and veterinary research and treatment for companion animals. Formerly known as NexxNow, Inc., the Company changed their name to Inolife Technologies, Inc. in January of this year. They have their headquarters in Raleigh, North Carolina and they trade on the OTC Bulletin Board.

The Company's wholly owned subsidiary is InoVet, Ltd. Their mandate is to provide state-of-the-art Veterinary Healthcare products and services. The primary goal of InoVet is to introduce and further develop Bone Marrow Transplantation and other cancer treatment procedures. This is for the benefit of companion animals (dogs and cats) that have lymphoma, other types of cancers, and other diseases that are currently incurable.

Inolife Technologies, Inc. continues to establish working relationships and partnerships with some of the top Veterinary Oncologists and Veterinary Cancer Researchers in the U.S. This is to help the Company bring revolutionary new treatment procedures to the companion animal healthcare market.

The laboratory the Company has collaborated with is a recognized industry leader in the fields of DNA testing and DNA analysis. InoHealth Products, Inc. came about to provide Human Healthcare products and services. The mission of InoHealth focuses solely on the licensing, introduction, marketing, promotion and sales of DNA and genetic testing and analytical products and services on a worldwide basis. The Company's partnership with InoHealth Products, Inc. will be in the marketing and promotion of such products and services.

These products and services will include the IHP DNA Predisposition Test. Their DNA predisposition testing service will reveal genetic predisposition for 25 diseases and conditions. The Company will also offer their IHP Ancestral Origins Test. With their DNA ancestry test, a DNA profile is compared against hundreds of global populations and fourteen anthropological regions whose collective genetic information is known and scientifically validated.

Another example of the products and services the Company will offer is their IHP FDA-Approved Paternity Test. Their FDA Approved Components DNA paternity testing system is a premium 16-marker DNA test. In addition, Inolife Technologies, Inc. will offer their IHP Parental Drug Testing Kit. This test is simple to perform alongside reporting that is clearly presented.

Today, InoLife Technologies, Inc. announced that they will provide and market a proprietary metabolizing test to physicians and practitioners to identify how a patient's genetic makeup may affect the body's response to Plavix (colpidogrel).

The Food and Drug Administration recently announced that Plavix must now carry a so-called "black box" warning label after a landmark study revealed that patients who were "non-responders" as a result of a genetic variation were "3.58 times more likely to have a fatal stroke or myocardial infarction."

InoLife Technologies feels that this is an important test for those who take Plavix or who may need to take Plavix in the future. The Company is very pleased that by addressing the black box warning, those who can be helped by this medication will be. The test will only be made available to physicians and medical professionals. It is not available for home use.

Inolife Technologies, Inc. (INOL) closed Wednesday’s trading session at $0.0940, up 3,381.48%, on 59,458,056 volume with 3,514 trades. The stock’s average daily volume over the past 60 days is 619,166 with a 52-week low/high of $0.0011/$0.22.

Northwest Biotherapeutics Inc. (NWBO)

Feed Blitz, Stock Traders Chat, Microcap Voice, Bull Rally, Hot OTC, Cool Penny Stocks, Investment U, Stock Rich, StockEgg.com, Standout Stocks, and Penny Invest reported earlier on Northwest Biotherapeutics Inc. (NWBO), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Headquartered in Bethesda, Maryland, Northwest Biotherapeutics Inc. is a biotechnology company. They focus on discovering, developing, and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company’s approach in developing cancer therapies utilizes their expertise in the biology of dendritic cells. This kind of white blood cell activates the immune system. The Company has two broad platform technologies, which are dendritic cell-based vaccines and therapeutic antibodies. Founded in 1996, Northwest Biotherapeutics Inc. trades on the OTCBB.

The Company's cancer therapies have been demonstrated in clinical trials to extend significantly both time to recurrence and survival. They do this while providing a superior quality of life with no debilitating side effects when compared with current therapies. The Company's platform technology, DCVax®, uses a patient's own dendritic cells, the starter engine of the immune system.

The dendritic cells are extracted from the body, loaded with tumor biomarkers or "antigens", thereby creating a personalized therapeutic vaccine. Injection of these cells back into the patient initiates a potent immune response against cancer cells, resulting in delayed time to progression and prolonged survival. Northwest Biotherapeutics Inc.'s second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.

Northwest Biotherapeutics Inc.'s lead product candidate is DCVax®-Brain. It targets Glioblastoma Multiforme (GBM). This is the most lethal form of brain cancer. DCVax®-Brain has entered a Phase II FDA-allowed clinical trial, designed and powered as a pivotal trial. Following this trial, the Company anticipates filing a biologic license application with the FDA for DCVax®-Brain. DCVax®-Prostate, which targets late stage prostate cancer, has also received clearance by the FDA to commence a Phase III clinical trial, designed and powered as a pivotal trial. The Company also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.

In October 2009, Northwest Biotherapeutics, Inc. announced further long-term follow-up data, for the period from January through September 2009, from their prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with GBM. During the update period, only one of the twenty patients treated with DCVax®-Brain (in addition to standard of care) died, and that patient had survived for nearly 7 years (80.5 months).

Overall, 85 percent of the patients treated with DCVax®-Brain in the Company's prior trials have lived longer than the median survival of 14.6 months, which is achieved with the full standard of care treatment available today. In addition, 22 percent of the patients treated with DCVax®-Brain have now reached or exceeded the 6-year survival mark. With standard of care treatment, less than 5 percent of GBM patients are still alive at 5 years.

On August 3, 2010, Northwest Biotherapeutics, Inc. announced further positive long-term follow-up data from their prior Phase I and Phase I/II clinical trials. The data through July 1, 2010, show that no patients died during the 9-month period since the last data update (through September 2009).

The data also show that median survival was three years, 33 percent of the patients reached 4-year survival, and 27 percent reached or exceeded 6-year survival (up from 22 percent who had reached or exceeded 6-year survival as of the last data update). The longest surviving patient to date has now exceeded 10 years.

Northwest Biotherapeutics Inc. (NWBO) closed today's trading session at $0.74, down 1.33%, on 354,351 volume with 82 trades. The stock’s average daily volume over the past 60 days is 291,508 with a 52-week low/high of $0.60/$1.79.

Ecologix Resource Group, Inc. (EXRG) ‏

Whisper from Wall Street, Wall Streets Hottest Stocks, Bloomfield Investment Club, Microcap Voice, Stockpalooza, HotOTC.com, Cool Penny Stocks, and Stock Rich reported on Ecologix Resource Group, Inc. (EXRG), and we highlight the Company, here at the QualityStocks Daily Newsletter. ‏

Ecologix Resource Group, Inc. is a natural resource company focused on the timber industry and production of alternative energy solutions. The Company manages a tropical hardwood forest in Cameroon, Africa. They grow and harvest trees for the use of lumber and other fine wood products. Ecologix continues to explore opportunities with other natural resources. This includes biofuel and oil, and they will evaluate other countries and geographies.

Founded in 2007, the Company formerly went by the name Battery Control Corp. They changed their name to Ecologix Resource Group, Inc. on July 14, 2009. Ecologix Resource Group, Inc. has their corporate headquarters in Beverly Hills, California. They trade on the OTCBB.

Cameroon has extensive tropical timber over approximately 21,245,000 hectares of forest coverage area. This includes a significant amount of commercial tree species. These species represent 75 percent of Cameroon's timber production.

Ecologix is currently operating within the NDeng NDeng rainforest on 3,000 hectares of land. This area is attractive due to its density and variety of tree species. The Company is also in the process of securing additional land concessions directly from local tribal counsels and through the acquisition of operating timber organizations.

Ecologix has secured the rights to 20,000 hectares of rainforest with an estimated 48,250,000 in the Massaka / Desoni region. This area is 325 km Southeast of Yaoundé. Massaka is a unique opportunity for Ecologix. It is a valuable concession for the harvesting of timber, however, the land can also easily undergo conversion for the responsible production of ethanol and biodiesel by creating a biofuel farm.

Ecologix has collaborated with the local tribe council and the central government of Cameroon to acquire concessions that already contain the richest types of hardwood in the world. The Company can supply timber to the local market and export products internationally. They are working closely with the United Nations to develop timber exploitation standards that will provide a global acceptance of environmentally friendly harvesting practices.

Ecologix Resource Group, Inc.'s current products include hardwood, timber products, and biomass. Ecologix will construct a timber cutting and processing plant. This gives the Company control over the entire logging process - from cut to planks. In addition, the Company's land concessions have been reserved for the responsible production of biofuel resources such as ethanol and biodiesel. Cameroon has the third largest biomass potential in Sub Saharan Africa.

On August 25, 2010, Ecologix Resource Group announced the appointment of Dr. Philip Rudolph Du Toit as president of African Administration, effective immediately. He will oversee Ecologix's African operations and business development. Dr. Philip Rudolph Du Toit is currently president and CEO of Transnational Automotive Group.

EcoLogix Resource Group, Inc. (EXRG) ‏ closed Wednesday’s session at $0.0060, up 20.00%, on 399,630 volume with 7 trades. The stock’s average daily volume over the past 60 days is 497,145 with a 52-week low/high of $0.0025/$0.082.

SciClone Pharmaceuticals, Inc. (SCLN)

Greenbackers, Wall Street Resources, Penny Invest, and StockEgg.com reported earlier on SciClone Pharmaceuticals, Inc. (SCLN), and we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

SciClone Pharmaceuticals, Inc. is a specialty pharmaceutical company. They have a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. Founded in 1989, SciClone Pharmaceuticals, Inc. has their headquarters in Foster City, California. The Company trades on the NASDAQ Global Market.

The Company's ZADAXIN® (thymalfasin or thymosin alpha 1) sells in more than 30 countries. It sells as a treatment for hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. ZADAXIN® has approval in Italy and 12 other countries as an adjuvant for influenza vaccine in immunocompromised patients or as an immune stimulant.

SciClone Pharmaceuticals continues to see commercial opportunity, mainly in Italy, in the potential of ZADAXIN to enhance the immune response to H1N1 pandemic flu vaccines. The Company reported initial results in early 2010 from a clinical study examining ZADAXIN's ability to enhance response to the H1N1 vaccine.

SciClone Pharmaceuticals, Inc.'s development pipeline of drug candidates includes thymalfasin, which is in clinical studies as an enhancer of vaccines. Their pipeline also includes thymalfasin, for stage IV melanoma. For this, the Company has reached agreement with the FDA on the design of a phase 3 trial. SciClone Pharmaceuticals, Inc. is actively seeking a partner to support a phase 3 clinical trial of thymalfasin as a potential treatment for stage IV melanoma.

Their SCV-07 is in clinical studies for the delay to onset of severe oral mucositis (OM) in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck. SCV-07 is also in a phase 2 trial for the treatment of HCV. The Company has exclusive commercialization and distribution rights to DC Bead™ in China. There, the product is under regulatory review.

SciClone Pharmaceuticals, Inc. also has exclusive commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm™ in China and Vietnam. The Company will seek regulatory approval for this drug.

SciClone Pharmaceuticals, Inc. (SCLN) closed today's trading session at $2.53, up 4.98%, on 250,168 volume with 1,051 trades. The stock’s average daily volume over the past 60 days is 347,785 with a 52-week low/high of $2.08/$5.33.

TerreStar Corporation (TSTR)

Hot OTC, Stock Rich, Stockpalooza, Bull Rally, Cool Penny Stocks, Stock Egg, Penny Invest, Microcap Voice, Greenbackers, Stock Fortune Teller, Stock Traders Chat, OTC Picks, Momentum Traders and Stock Stars reported on TerreStar Corporation (TSTR), and we highlight the Company, here at the QualityStocks Daily Newsletter.

TerreStar Corporation is the controlling shareholder of TerreStar Networks Inc. and TerreStar Global Ltd. TerreStar Corporation, through their subsidiaries, engages in the mobile communications business in North America. Formerly known as Motient Corporation, the Company changed their name to TerreStar Corporation in August 2007. Founded in 1988, the Company trades on the NASDAQ Global Market. They have their corporate headquarters in Reston, Virginia.

As a majority owned subsidiary of TerreStar Corporation, TerreStar Networks mission is to provide a reliable and secure satellite terrestrial mobile broadband network. This network will provide voice, data and video services dedicated to helping solve the critical communication and business continuity challenges faced by government, emergency responders, enterprise businesses and rural communities. TerreStar expects to offer next generation mobile communications through a network of partners and service providers to users who need coverage anywhere throughout the U. S. and Canada.

TerreStar Corporation, through TerreStar Global Ltd., also intends to build, own, and operate a Pan-European integrated mobile satellite and terrestrial communications network. This is to address public safety and disaster relief. It is also to provide broadband connectivity in rural regions to help narrow the digital divide.

TerreStar Corporation's geostationary satellite (TerreStar-1) provides coverage to the Continental United States, Canada, Puerto Rico, U.S. Virgin Islands, Hawaii and Alaska. Their 20MHz of spectrum is contiguous in the 2GHz band and suits voice, data and content delivery.

TerreStar-1 offers approximately 500 dynamically configurable spot beams. This allows the Company to allocate spectrum and capacity using Ground Based Beam Forming (GBBF). This allows for significant efficiency during day-to-day operations and capacity as needed in a situational crisis.

TerreStar-1 launched on July 1, 2009. It was constructed by Space Systems/Loral and is the world's largest and most powerful commercial satellite ever launched. It has an antenna almost 60 feet across. TerreStar can deliver services over a wide spectrum of commercially available wireless devices. These include cell phones, PDAs, laptops and Land Mobile Radios (LMRs).

The Company also has their TerreStar GENUS™ Smartphone. It is the world's first integrated satellite and cellular smartphone. It has premium features such as a single phone number for satellite and cellular service, touchscreen, 3.0 megapixel camera, MicroSD slot, WiFi®, Bluetooth®, GPS and full QWERTY keypad. The device ensures "always on" connectivity for critical communications via AT&T's voice and data network and TerreStar's next generation satellite voice and data services

TerreStar Corporation (TSTR) closed Wednesday’s trading session at $0.3150, up 14.55%, on 3,698,797 volume with 3,087 trades. The stock’s average daily volume over the past 60 days is 1,291,896 with a 52-week low/high of $0.184/$2.95

QuinStreet, Inc. (QNST)

We are highlighting QuinStreet, Inc. (QNST), here at the QualityStocks Daily Newsletter.

Headquartered in Foster City, California, QuinStreet, Inc. is one of the world's largest online marketing and media companies. Founded in April 1999, the Company is a top five online media buyer. Clients count on them to be the best source of customer acquisition at scale. QuinStreet, Inc. trades on the NASDAQ Global Select Market.

QuinStreet, Inc. is a search-engine marketing pioneer and is one of the largest PPC (pay-per-click) buyers in the world. The Company manages one of the largest proprietary networks on the Internet. They have expertise in every major form of online traffic. This includes their owned and operated destination sites, PPC search, third-party publishers, opt-in email, and newsletters.

The Company manages brand and regulatory compliance using proprietary technologies and staff. They do not support or use spyware, spam or promotions that take advantage of consumers. They have expertise in select industry verticals, which enables them to garner the best results for their clients. Their expertise is in online messaging, segmentation, and impact in their verticals.

QuinStreet, Inc. offers online messaging, email broadcasting, search engine marketing, and brand management services. They deliver targeted results across numerous verticals. The Company caters to Education, Home Services, Financial Services, B2B, Medicine/Health, Premium Brand Advertising, Career Services, and Travel sectors. They also operate a web portal. This portal offers a comprehensive consumer information service and companion insurance brokerage service to self-directed insurance shoppers.

The Company delivers qualified clicks and inquiries at low cost and with greater scalability. Their full-service approach and market-leading capabilities enable them to increase their clients' sales while reducing their clients' customer acquisition costs by as much as two-thirds.

They continually develop technologies that drive media yield, improve qualified click quality and volume, and protect their clients' brand integrity. QuinStreet, Inc. offers their Vertical Marketing Focus. They have extensive expertise in each individual vertical they serve, heightened by rigorous analytics. They offer their Targeted Media Advantage. They achieve broad reach using virtually every online media channel. This is from high-traffic placements on their company owned and operated content sites, pay-per-click (PPC) search, and third-party publishers.

On August 9, 2010, QuinStreet, Inc. announced their financial results for the fiscal fourth quarter and fiscal year ended June 30, 2010. For the fourth quarter of fiscal year 2010, the Company reported total revenue of $88.5 million, an increase of 31 percent over the fourth quarter of fiscal 2009. For the fiscal year ended June 30, 2010, the Company reported total revenue of $334.8 million, an increase of 29 percent over fiscal 2009. They reported net income of $6.4 million, or $0.13 per diluted common share, for the fourth quarter of fiscal 2010.

QuinStreet, Inc. (QNST) closed Wednesday’s trading session at $11.25, up 4.85%, on 512,802 volume with 2,001 trades. The stock’s average daily volume over the past 60 days is 273,674 with a 52-week low/high of $9.79/$18.25.

UQM Technologies Inc. (UQM)

FeedBlitz, SmallCap Voice, Green Chip Stocks, All about trends, Greenbackers, and Dubai Penny Stocks reported earlier on UQM Technologies Inc. (UQM), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Founded in 1967, UQM Technologies Inc. is a developer and manufacturer of power dense, high efficiency, brushless permanent, magnet electric motors, generators, and power electronic controllers. A major emphasis of the Company is developing products for the alternative energy technologies sector. These include propulsion systems for electric, hybrid electric, plug-in hybrid electric and fuel cell electric vehicles, under-the-hood power accessories and other vehicle auxiliaries. These systems are also for distributed power generation.

Trading on the NYSE Amex, the Company has their headquarters in Longmont, Colorado. Their engineering and product development center, and motor manufacturing operations are at this location as well.

UQM Technologies Inc. offers their customers motor/generator and power electronics manufacturing and application engineering as well as power-system integration services. They also offer custom engineered electric motors, generators, and related electronic converters for the automotive, military, and distributed power markets. UQM Technologies Inc. services also include feasibility studies, specification evaluation, and software development.

Their wholly owned subsidiary UQM Power Products, Inc. is also in Longmont, Colorado. UQM Power Products conducts motor manufacturing operations and performs the final assembly of UQM® permanent magnet propulsion motors. These are for vehicle auxiliary systems, wheelchairs, compressor drive motors for fuel cells, and fan blower motors used in military aircraft air conditioning systems.

This subsidiary produces electric and hybrid electric propulsion systems, DC-to-DC converters, DC-to-AC electronic power inverters, generators, propulsion motors, vehicle auxiliary actuator motors, electric auxiliary motors, auxiliary power units, and motor controllers.

On July 21, 2010, UQM Technologies, Inc. announced that they released a new 200 kW motor/generator system. This is for use in electric propulsion and generator applications. The new system extends the peak power available in the Company’s 405 mm diameter frame size to 200 kW, has a continuous power rating of 115 kW, and delivers peak torque of 900 N-m. UQM® propulsion systems and generators are available in a variety of power levels in either a 280 mm diameter frame size or a larger 405 mm diameter frame size.

UQM Technologies Inc. (UQM) closed Wednesday’s trading session at $2.21, up 7.28%, on 200,805 volume with 839 trades. The stock’s average daily volume over the past 60 days is 288,571 with a 52-week low/high of $2.065/$7.45.

Nile Therapeutics, Inc. (NLTX)

We are highlighting Nile Therapeutics, Inc. (NLTX), here at the QualityStocks Daily Newsletter.

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Headquartered in San Mateo, California, the Company is initially focusing their efforts on developing their lead compound, CD-NP, although they are also developing CU-NP. Founded in 2005, Nile Therapeutics, Inc. trades on the NASDAQ Capital Market.

The Company's CD-NP is a novel rationally designed chimeric peptide. It is in clinical development for an initial indication of acute decompensated heart failure (ADHF). Scientists at the Mayo Clinic's cardio-renal research labs rationally designed CD-NP. The design of CD-NP is to preserve the favorable effects of current therapies while preventing or attenuating the hypotensive response, and enhancing or preserving renal function. In addition to an initial indication for ADHF, CD-NP has potential use in other indications. These include preservation of cardiac function subsequent to AMI, and prevention of renal damage subsequent to cardiac surgery.

Nile Therapeutics, Inc. made progress during 2009 in the clinical development of CD-NP. In July 2009, the first patient received dosing in a single blind, placebo-controlled Phase II clinical trial. The design of the trial is to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with acute heart failure and renal function insufficiency. The study also contains several exploratory efficacy endpoints to provide insight into the potential for CD-NP to enhance renal function in acute heart failure patients.

Thirty subjects completed dosing in study, as of March 1, 2010. The Company submitted a protocol amendment at the end of 2009, to enable them to add up to three additional cohorts of patients, which increased potential enrollment in the study to approximately 75 patients. Interim top-line safety data from the on-going Phase II study suggests that CD-NP is well tolerated at doses of 1.25 and 2.5 ng/kg/min.

On July 7, 2010, Nile Therapeutics, Inc. announced that they completed the dosing of the last patient in NIL-CDNP-CT005, an open-label, single-blind, placebo-controlled Phase II study of CD-NP in patients with acute decompensated heart failure, or ADHF. The design of the study was to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with ADHF and mild to moderate renal insufficiency. Additional endpoints included assessments of symptom relief and effects on biomarkers of heart failure and renal function. Final results from the study are expected in the fourth quarter of 2010.

Nile Therapeutics, Inc.'s CU-NP is a novel rationally designed natriuretic peptide in pre-clinical development. CU-NP consists of amino acid chains identical to those produced by the human body, specifically the ring structure of C-type Natriuretic Peptide (CNP) and the N- and C-termini of Urodilatin (URO).

Researchers at Mayo designed CU-NP to combine the favorable hemodynamic venodilating effects of CNP generated via NPR-B receptor agonism, with the beneficial renal effects of URO generated via NPR-A receptor agonism. In-vivo studies have shown CU-NP to increase natriuresis, diuresis, and glomerular filtration rate (GFR) in a dose dependent manner. These studies have also shown CU-NP to decrease cardiac filling pressure, and inhibit the renin-angiotensin system without inducing significant hypotension.

Nile Therapeutics, Inc. (NLTX) closed Wednesday’s trading at $0.57, up 3.64%, on 59,187 volume with 77 trades. The stock’s average daily volume over the past 60 days is 95,355 with a 52-week low/high of $0.29/$2.23.

The QualityStocks Company Corner

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.0028, up 21.74%, on 532,300 volume with 6 trades. The stock’s average daily volume over the past 60 days is 62,769 with a 52-week low/high of $0.001/$0.45.

Consorteum Holdings, Inc. (CSRH) announced that on July 27, 2010, their client, First Nations Financial Services ("FNFS"), successfully deployed their first pilot program of MasterCard benefits cards. As previously agreed to, FNFS funded the expenses of the pilot, which was launched with the Madawaska Maliseet First Nation Community.

Consorteum Holdings, Inc. (CSRH) is focused on providing financial services, electronic transaction processing and management services to financial institutions, healthcare, government, public and private sector companies. The company’s services provide customized, innovative technology solutions that create, augment and enhance their clients’ existing financial, payment and transactional processing systems.

The company offers clients a long-term strategic plan utilizing the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create exceptionally customized programs. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new revenues. 

Consorteum’s strategy is to capitalize on the global opportunities within the growing financial services, payment and transaction processing marketplace. The utilized business model generates revenues on every transaction touched, thus providing long-term, sustainable income. The company has strategically designed its business initiatives to create significant repetitive transactions on an ongoing basis. Additional company revenues are generated from consulting services, project minimums and management fees. 

The company is jointly led by CEO Craig Fielding and President & COO Quent Rickerby. Mr. Fielding brings a wealth of expertise in the payments industry, in both local and international payment processing, along with HR-specific business management expertise, leadership, customer development and acquisition skills. Mr. Rickerby brings over two decades of business management, international and domestic sales experience, new company start-up, payment processing, project management, business development, negotiations, relationship management and strategic company direction.Disclaimer

Consorteum Holdings, Inc. Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings Inc. Announces New Appointments and Organizational Changes

Consorteum Holdings Inc. Announces CFO Appointment

Consorteum Holdings Inc. Announces an Agreement with Rosebank Capital to Raise $1,500,000 for MyGolf Rewards Canada

Micro Identification Technologies Inc. (MMTC)

The QualityStocks Daily Newsletter would like to spotlight Micro Identification Technologies Inc. (MMTC) Today, Micro Identification Technologies, Inc. closed trading at $0.021, even with yesterday's close, on 760,610 volume. The stock’s average daily volume over the past 90 days is 214,429.

Micro Identification Technologies Inc. (MMTC) today announced that it is making significant progress in the production of the MIT 1000. This is important, since demand for the revolutionary system, already used by the U.S. Department of Agriculture and the Japanese Ministry of Food Safety, has been building. Their success in growing manufacturing capability is due largely to the company’s recent manufacturing alliance with OSI Optoelectronics (OSIO), a subsidiary of OSI Systems (NASDAQ: OSIS).

Micro Identification Technologies Inc. (MMTC) is focused on becoming a global leader in developing, supporting and marketing rapid systems and processes that detect and identify microbial organisms. For several years the company has been working on the development of a breakthrough, laser-based microbial identification technology. This technology has been designed to be extremely fast and easy to use while not relying on conventional chemical or biological processing, fluorescent tags, gas chromatography or DNA analysis.

The system works by measuring scattered light intensity as individual microbes pass through a laser beam. The intensity pattern of the scattered light is a direct consequence of the size, shape and external and internal optical characteristics of the microbe. By measuring scattered light at specific angles, MIT’s system detects and differentiates objects the size of bacteria, protozoa, yeasts and molds.

The company’s technology offers significant advantages over today’s methods of microbial detection, including lower cost, rapid results, easier use and the ability to test for multiple bacteria in one process. The system is statistically based and includes a unique MIT Microbe Library of pre-measured light scattering identifiers - or fingerprints - derived from the measurements of tens of thousands of individual microbes for each species and subspecies to be detected.

MIT’s technology has the potential to revolutionize the $5 billion rapid microbial test market by annually saving thousands of lives and tens of millions of dollars. Since 1998, the industry has had an annual expansion of 9.2 percent - with growth projections for 30 percent annually. MIT is well positioned with its cutting-edge microbial technology as demand continues to soar as a result of major health, safety and homeland security issues. Disclaimer

Micro Identification Technologies Inc. Blog

Micro Identification Technologies Inc. News:

MIT Initiates Expansion Plans Enabled by Recently Completed Manufacturing and Financing Agreements

MIT Contracts OSI Optoelectronics to Manufacture the MIT 1000 Rapid Microbial Identification System

U.S. Equity News Features Micro Identification Technologies in the Fight Against Bacteria

Simulated Environment Concepts, Inc. (SMEV)

The QualityStocks Daily Newsletter would like to spotlight Simulated Environment Concepts, Inc. (SMEV). Today, Simulated Environment Concepts, Inc. closed trading at $0.0170, up 41.67%, on 283,900 volume with 15 trades. The stock’s average daily volume over the past 60 days is 183,149 with a 52-week low/high of $0.001/$0.07.

Simulated Environment Concepts, Inc. (SMEV) is focused on manufacturing and distributing their patented SpaCapsule® as well as continued innovation in the areas of anti-aging, cosmetics, relaxation, cellulite reduction, and weight loss. Finding use in numerous environments such as relaxation centers, golf clubs, ski lounges, gyms, and health clubs, the SpaCapsule® provides next generation de-stressing and relaxation.

The company’s founders, Dr. Ella Frenkel and Dr. Ilya Spivak, initially capitalized Simulated Environment Concepts Inc. with several million dollars of their own money. With this initial investment, the company worked on, and succeeded in developing, the sleek and stylish looking pressurized dry water massage relaxation station.

SpaCapsule® is a full body massage, aromatherapy, audio and video entertainment system. The capsules are fused with advanced modern technology and healing methods of aromatherapy and audiovisual relaxation techniques, incorporating proprietary water-jet and pressure-jet technology that requires no on-site plumbing. Weighing approximately 500 lbs, the capsule only requires standard electric service.

Simulated Environment Concepts, Inc. (SMEV) anticipates progressive and consistent growth over the next six years. With individuals spending billions of dollars on de-stressing, weight loss, anti aging, cosmetics, massage and physical rehabilitations, the company is in a position to experience explosive growth from current levels. Disclaimer

Simulated Environment Concepts, Inc. Blog

Simulated Environment Concepts, Inc. News:

Simulated Environment (SMEV) Continues Overseas Expansion: New Agreement with UK Based Firm Follows Multi-Million Dollar Deals in France and UAE- Top Ten Stocks to Watch for Tuesday, August 24, 2010

Simulated Environment (SMEV) Continues Overseas Expansion: New Agreement with UK Based Firm Follows Multi-Million Dollar Deals in France and UAE- Top Ten Stocks to Watch for Tuesday, August 24, 2010

Simulated Environment Concepts and UK Partner Aspire Consulting Expand Virbralife Fitness Program With Twelve SpaCapsule Units

Simulated Environment Concepts Attains Pink Sheets Current Information Status

eDOORWAYS Corporation (EDWY)

The QualityStocks Daily Newsletter would like to spotlight eDOORWAYS Corporation (EDWY) Today eDoorways Corporation closed trading at $0.0029, up 16.00%, on 172,194 volume with 5 trades. The stock’s average daily volume over the past 60 days is 3,583,898 with a 52-week low/high of $0.0011/$0.16.

eDOORWAYS Corp. (EDWY) and Escue Polo LLC are joining teams to launch the Escue Polo PowerChannel. Escue will use the new channel to augment their current website located at www.escue-polo.com.

eDOORWAYS Corp. (EDWY) is committed to solving lifestyle problems for consumers while driving traffic to suppliers and service providers who offer innovative merchandise and solutions. The company has the potential to completely change the future landscape of business by offering a unique and comprehensive service that saves consumers valuable time and money. By uniting a consumer with the larger global consumer community, retailers, and manufacturers in an effective new way, eDOORWAYS promotes “dynamic” commerce, as opposed to the static model currently in existence.

The Company plans to capitalize on several emerging new trends. These newly created opportunities include: the large success of Web 2.0 Internet community service offerings such as MySpace, the movement towards niche marketing and targeted advertising, the introduction of new technologies that enable instantaneous, online presentation of information, and the rising consumer preference for using the Internet to gain information before making purchasing decisions.

eDOORWAYS plans to introduce local services using a city-by-city strategy that will minimize capital requirements, reduce staffing requirements, and optimize generated revenues. Ten major cities are targeted for launch in the first year. Advertising, PR campaigns and viral word-of-mouth will be used to give a public presentation to experts as well as educate the market.

The key benefits offered to consumers include a higher level of engagement with vendors, trusted information from other consumers, and superior customer service. Revenues will be generated through advertising placement fees, premium services, preferential placement fees, and a percentage of sales transactions. eDOORWAYS' progressive vision and professional management team makes it an attractive investment opportunity. Disclaimer

eDOORWAYS Corporation Blog

eDOORWAYS Corporation News:

eDoorways Welcomes Escue's New Polo PowerChannel

eDoorways Announces Launch of Virtual Martial Arts Competition PowerChannel

In A New Audio Interview at SmallCapVoice.com, Dr. Ramiro Jordan Discusses the New Technology from eDoorways Corporation

Micro Identification Technologies, Inc. (MMTC) Builds Manufacturing To Meet Growing Demand

Micro Identification Technologies Inc., developers of the MIT 1000, a patented microbial identification system that can identify bacteria faster and less expensively than any other method available, today announced that it is making significant progress in the production of the MIT 1000. This is important, since demand for the revolutionary system, already used by the U.S. Department of Agriculture and the Japanese Ministry of Food Safety, has been building. Their success in growing manufacturing capability is due largely to the company’s recent manufacturing alliance with OSI Optoelectronics (OSIO), a subsidiary of OSI Systems (NASDAQ: OSIS), to produce the MIT 1000. OSIO has manufacturing facilities in California, Malaysia, and India.

There’s nothing like the MIT 1000. It can identify a wide range of potentially dangerous bacteria in minutes instead of days, without chemical or biological agents, without fluorescent tags, gas chromatography, or DNA analysis, saving money as well as time. With the increased calls for food safety, revenues for rapid testing methods have expanded at an annual rate of over 9% since 1998, and already exceed $5 billion annually. Current growth projections are at 10.2% annually, reaching $6.2 billion by 2013.

MIT’s Executive VP and COO, John Ricardi, commented on the manufacturing progress. “All of OSIO’s world class facilities are ISO 9001:2000 certified, FDA registered and GMP compliant making them the perfect company to fabricate MIT’s systems for food safety applications as well as planned pharmaceutical and clinical diagnostic applications. While we are predicting quantity deliveries of the MIT 1000 System by the end of this year, initially the systems will be built in OSIO’s California facility, as volume increases, fabrication will move to one of their lower cost overseas facilities enabling MIT to improve future profit margins.”

To help fund the growth, MIT has entered into a three-year $5 million equity agreement with Boston-based private equity firm Dutchess Capital. MIT CEO, Michael Brennan, stated, “We have been very pleased working with Dutchess, which has an excellent track record in the investment banking industry and has been a leading provider of private equity for over 10 years. Their successful background was the primary reason we selected them to be one of our partners.”

Consorteum Holdings, Inc. (CSRH) Successfully Deploys Payment Cards Pilot Program for First Nations

Consorteum Holdings, Inc. was pleased to announce this morning that on July 27, 2010, its client, First Nations Financial Services (“FNFS”), deployed its first pilot program of MasterCard benefits cards. As previously agreed to, FNFS funded the expenses of the pilot, which was launched with the Madawaska Maliseet First Nation Community, in Edmundston, New Brunswick, Canada.

Targeted at the community’s administration group, the pilot will provide valuable data for expansion of the program. According to the press release, Consorteum Holdings will launch a multi-location pilot rollout in the next 2-3 months subject to the success of the pilot and to receipt of additional funding. This initial deployment is the first of a suite of products and services, including point-of-sale services as well as additional banking, credit and related financial offerings, for aboriginal communities in North America.

Mr. John Bernard, a First Nation’s partner in the initiative, stated, “This pilot will enable us to clearly identify the requirements for rollout of the initiative on a much larger scale. We are very pleased with the progress and look forward to the next stages of deployment.”

Chief Joanna Bernard of the Madawaska Maliseet Community said, “This pilot will provide important feedback on how we can launch the initiative nationally. We are pleased to participate in the program, and given the initial feedback, we look forward to a successful national launch.”

Craig Fielding, CEO of Consorteum Holdings, added, “This program will contribute dividends back to participating communities, and as an aboriginal sponsored program, provides much needed services to the communities. Collectively we expect the program to be beneficial and profitable to all parties.”

US Natural Gas Corp (UNGS) Expands Acreage in W. Virginia

US Natural Gas, www.usnatgascorp.com – the independent energy firm focused on the acquisition of mature, long-lived oil and natural gas resources, reported acquisition of 120 acres of mineral rights in W. Virginia’s Wayne County today.

With its primary sites in Kentucky and West Virginia’s Appalachian Basin, the Company’s acquisition in the Lincoln District (Radnor Quad) of Wayne County is surrounded by several proven and highly productive wells drilled to an average of 5k feet and bearing no significant explorative efforts to date.

President of UNGS, Wayne Anderson, commented on the addition of acreage in West Virginia and noted the particularly promising potential of this new resource as nicely suited for one of the Company’s upcoming drilling programs.

Anderson also cited ongoing developments with the Wilon Resources, Inc. acquisition, reporting with pleasure to the Company’s shareholders that 43 wells are in production and delivering to Columbia Gas Transmission’s pipeline.

Projections indicate another six to seven wells will be in production by the middle of this month, after the Sulfa Treat vessels – required due to the high hydrogen sulfide output of these wells in particular – are installed and ready.

Anderson also outlined the imminent completion of several pending deep wells to shareholders. This Completion project, on wells which were drilled within the past four years, will launch this quarter.

Daily production output company-wide has steadily improved in recent months, according to Anderson, as UNGS has set about its reworking and completion efforts. The Company is still in the market for additional opportunities to grow shareholder returns by acquiring underutilized assets.

Kore Nutrition (KORE) Retains LBM Sales to Market and Distribute ALL IN Beverage Product Line

Kore Nutrition Inc. and its wholly owned subsidiary Go All In Inc. today announced their business partnership with LMB Sales Inc., in which LBM will represent and market ALL IN’s non-alcoholic beverage products throughout the Western United States.

LBM will serve as one of Kore’s initial key distributors. The California-based marketing and distribution company has a network of established relationships with some of the largest and most well-known retail distributors in the U.S. and has a successful track record of attracting new retail clients. Kore said it will first target major retail store chains such as Kroger, Walgreens, 7-Eleven, Costco and Walmart for distribution of ALL IN products.

ALL IN president and CEO David Powley said the company’s goal is to utilize LMB’s distribution network to successfully penetrate the beverage market.

“LMB Sales has significant relationships with some of the largest retailers in the United States, which will enable ALL IN’s healthier alternative energy drinks to quickly become a household name to the millions of beverage consumers,” Powley stated in the press release.
LMB is expected to play an “integral role” in the North American marketing and distribution of ALL IN products, with upcoming plans to offer the products in casinos and retail outlets across California, Nevada and Arizona.

 


Sponsors of the Day

 

The QualityStocks Public Company Sponsor News

Micro Identification Technologies Inc. (MIT) (MMTC) MIT Initiates Expansion Plans Enabled by Recently Completed Manufacturing and Financing Agreements

QualityStocks


 

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

Home | Blog | Video | Market Basics | Media | Partners | Clients | About Us | Contact Us | Disclaimer | Unsubscribe
Copyright 2006-2009 QualityStocks 3370 N. Hayden Rd. Suite 123-591 Scottsdale, AZ 85251 480-374-1336